Insider Trading activities at Pharmacyte Biotech, Inc. (PMCB)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pharmacyte Biotech, Inc. (PMCB) since 2026 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Pharmacyte Biotech, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1157075.

Total stock buying since 2026: $128,720.
Total stock sales since 2026: $0.
Total stock option exercises since 2026: $0.


2 insiders reported insider trading activities at Pharmacyte Biotech, Inc. (PMCB):
Insider trading activities of Silverman Joshua
Insider trading activities of Schechter Jonathan

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Pharmacyte Biotech, Inc. (PMCB).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2026 160,000 $128,720 0 $0 0 $0

Table 2. Monthly summary of insider trading at Pharmacyte Biotech, Inc. (PMCB).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2026-01 160,000 $128,720 0 $0 0 $0

Table 3. Detailed insider trading at Pharmacyte Biotech, Inc. (PMCB)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2026-01-07 Schechter Jonathan Buy 20,000 .84 16,880
2026-01-07 Silverman Joshua (CEO and President) Buy 40,000 .83 33,320
2026-01-06 Schechter Jonathan Buy 20,000 .79 15,800
2026-01-06 Silverman Joshua (CEO and President) Buy 30,000 .79 23,670
2026-01-05 Schechter Jonathan Buy 20,000 .78 15,560
2026-01-05 Silverman Joshua (CEO and President) Buy 30,000 .78 23,490

Insider trading activities including stock purchases, stock sales, and option exercises of PMCB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Pharmacyte Biotech, Inc. (symbol PMCB, CIK number 1157075) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.